MedCity News December 1, 2021
Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.
Add the skin microbiome to Sanofi’s growing list of targets for its new messenger RNA vaccines strategy. The pharmaceutical giant is acquiring Origimm Biotechnology, an early clinical-stage startup that is developing therapeutic vaccines to address diseases and infections associated with skin-colonizing microbes.
No financial terms were disclosed in the Wednesday announcement of the deal, which the companies expect to close early this month.
The research of Vienna, Austria-based Origimm research focuses on the discovery of virulent skin microbes that cause disease or lead to infection. Origimm says...
Today's Sponsors
Today's Sponsor